| Novo Allé | Phone: +45-4444-8888 |
| Bagsværd | Fax: +45-4449-0555 |
| 2880 | |
| Denmark | 
Map This Company |
Novo Nordisk A/S Rankings
 #115 in FT Global 500 (June 2011) |
Company Description
Until there is a cure for diabetes, Novo Nordisk will stay busy, and as long as diabetes is on the rise, it will likely stay profitable. It is one of the world's leading producers of human insulin, insulin analogues, injection devices, and education materials. It makes modern insulin analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin) and the FlexPen, a pre-filled injection tool. The firm also has products in the areas of hemostasis management (blood clotting), human growth hormone, and estrogen replacement therapy. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls the voting power in Novo Nordisk.
Novo Nordisk A/S Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - OMX Copenhagen: NOVO B Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 32,000 |
Executives
58 executives listed for Novo Nordisk A/S's Bagsværd, Denmark location.
| Chairman | Sten Scheibye | |
|---|---|---|
| Vice Chairman | Goron Ando | |
| President and CEO | Lars Rebien Sørensen |